The estimated Net Worth of Charles J. Collins is at least $2.39 Million dollars as of 17 July 2020. Charles Collins owns over 22,748 units of Luminex Corp stock worth over $1,771,710 and over the last 7 years Charles sold LMNX stock worth over $615,658.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Collins LMNX stock SEC Form 4 insiders trading
Charles has made over 4 trades of the Luminex Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently Charles exercised 22,748 units of LMNX stock worth $424,023 on 17 July 2020.
The largest trade Charles's ever made was exercising 37,252 units of Luminex Corp stock on 15 July 2020 worth over $593,424. On average, Charles trades about 8,311 units every 78 days since 2018. As of 17 July 2020 Charles still owns at least 47,897 units of Luminex Corp stock.
You can see the complete history of Charles Collins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Luminex Corp
Over the last 21 years, insiders at Luminex Corp have traded over $55,627,864 worth of Luminex Corp stock and bought 685,936 units worth $10,423,148 . The most active insiders traders include G Walter Ii Loewenbaum, Douglas C Bryant, and Laurence E Hirsch. On average, Luminex Corp executives and independent directors trade stock every 26 days with the average trade being worth of $888,944. The most recent stock trade was executed by Harriss T Currie on 1 March 2021, trading 5,325 units of LMNX stock currently worth $97,235.
What does Luminex Corp do?
The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.
What does Luminex Corp's logo look like?
Complete history of Charles Collins stock trades at Luminex Corp
Luminex Corp executives and stock owners
Luminex Corp executives and other stock owners filed with the SEC include:
-
Nachum Shamir,
President, Chief Executive Officer, Director -
Harriss Currie,
Chief Financial Officer, Senior Vice President - Finance, Treasurer -
Richard Rew,
Senior Vice President, General Counsel and Corporate Secretary -
Todd Bennett,
Senior Vice President - Global Sales and Customer Operations -
Randall Myers,
Senior Vice President - Global Manufacturing and Quality -
Kenneth Samet,
Independent Director -
Kevin McNamara,
Independent Director -
Jimmy Kever,
Independent Director -
Edward Ogunro,
Lead Independent Director -
Thomas Erickson,
Independent Director -
Stephen Eck,
Independent Director -
Dijuana Lewis,
Independent Director -
Eric Shapiro,
Senior Vice President - Global Marketing -
Nancy Fairchild,
Senior Vice President - Human Resources -
Chuck Collins,
Senior Vice President - Research and Development -
Robert J Cresci,
Director -
Tadd S. Lazarus,
SVP, Chief Medical Officer -
Jay B Johnston,
Director -
Russell S Bradley,
VP, Strategic Planning and Bus -
G Walter Ii Loewenbaum,
Director -
Jim D Kever,
Director -
Gregory J Gosch,
Vice President - Marketing -
Charles J. Collins,
SR VP, R&D - US -
John C Carrano,
VP, Research & Development -
J Stark Phd Thompson,
Director -
Douglas C Bryant,
EVP, Chief Operating Officer -
James W Jacobson,
VP, Research & Development -
Oliver H Meek,
VP, Manufacturing -
Randel S Martin,
VP, Marketing/Sales -
Kristi M Richburg,
Controller -
G Walter Ii Loewenbaum,
Director -
C Thomas Caskey,
Director -
Laurence E Hirsch,
Director -
Fred C Jr Goad,
Director -
Jeremy K Bridge Cook,
VP, Luminex Molecular Diagn -
Michael F Pintek,
SVP Operations -
Patrick J Balthrop,
President, Chief Exec. Officer -
Timothy R Dehne,
VP, Systems R&D -
David S Reiter,
General Counsel & Secretary -
Gerard Vaillant,
Director